Ribozyme-mediated inhibition of expression of leukocyte-type 12-lipoxygenase in porcine aortic vascular smooth muscle cells

Circulation Research
J L GuJ Nadler

Abstract

Activation of a leukocyte-type 12-lipoxygenase (12-LO) has been proposed to be an important mechanism for angiotensin II- and glucose-induced vascular smooth muscle cell growth. Currently, no specific pharmacological inhibitors for the leukocyte-type 12-LO are available to test this hypothesis. We have therefore designed a chimeric DNA-RNA hammerhead ribozyme to produce cleavage at the first GUC sequence at nucleotide 7 of porcine leukocyte 12-LO mRNA. The ribozyme was tested in vitro with a 206-base 12-LO mRNA as substrate. We observed that the ribozyme specifically and dose-dependently cleaved porcine leukocyte 12-LO mRNA at the predicted site under physiological temperature. Furthermore, we also efficiently delivered the ribozyme into porcine aortic vascular smooth muscle cells by transfection with cationic liposomes. The ribozyme caused a dose-dependent decrease in levels of porcine leukocyte-type 12-LO mRNA in these cells and was more potent than an antisense oligonucleotide directed against porcine leukocyte 12-LO. The 12-LO ribozyme also attenuated 12-LO protein levels in the cells. The action of the ribozyme was primarily a result of its catalytic activity, since a modified ribozyme that lacks catalytic activity showed ...Continue Reading

References

Jun 15, 1979·Biochemical Pharmacology·G A HiggsJ R Vane
Jan 1, 1992·Advances in Enzyme Regulation·T FunatoK J Scanlon
Aug 31, 1992·Biochemical and Biophysical Research Communications·R NatarajanJ L Nadler
Feb 20, 1992·Journal of Molecular Biology·M SioudO Førre
Nov 27, 1990·Biochemistry·D E RuffnerO C Uhlenbeck
Apr 1, 1991·Journal of Medicinal Chemistry·H ChoT Ishihara
Mar 9, 1990·Science·N SarverJ J Rossi
Jan 1, 1986·Annual Review of Biochemistry·T R Cech, B L Bass
Feb 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·S ParthasarathyD Steinberg
Jul 1, 1987·Hypertension·I AntonipillaiR Horton
Apr 14, 1982·Biochemical and Biophysical Research Communications·K Sekiya, H Okuda
Jun 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·R NatarajanJ Nadler

❮ Previous
Next ❯

Citations

Dec 1, 1995·Current Opinion in Biotechnology·A Chonn, P R Cullis
Jan 7, 1998·Bioorganic & Medicinal Chemistry·F BurlinaJ L Fourrey
May 4, 2001·Antisense & Nucleic Acid Drug Development·E HovigJ Goodchild
Sep 12, 2002·Expert Opinion on Therapeutic Targets·John Goodchild
Dec 1, 2001·Expert Opinion on Biological Therapy·N DüzgünesM C Pedroso de Lima
Jul 19, 2001·Cancer Investigation·L Wright, P Kearney
Oct 26, 2010·Progress in Lipid Research·Anca D DobrianJerry L Nadler
Jan 25, 2002·Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists·S P Lyngstadaas
Aug 18, 2010·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Nikolaos P MastroyiannopoulosLeonidas A Phylactou
Aug 14, 1999·The Journal of Biological Chemistry·J P WangB B Teng
Oct 10, 2002·American Journal of Physiology. Renal Physiology·Marpadga A ReddyRama Natarajan
Jul 4, 1998·Biochimica Et Biophysica Acta·K KonopkaN Düzgüneş

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.